Please note: Work is currently underway to update content available on this site.
Director Letters (formerly MELs/CELs/HDLs etc) are currently being reviewed to ensure it is clear which publications are current, superseded or obsolete.
Director Letters (formerly MELs/CELs/HDLs etc) are currently being reviewed to ensure it is clear which publications are current, superseded or obsolete.
Publication #3632
Reference
Name
The risk sharing scheme for disease modifying therapies in MS
Categories
Scottish Government
Organization
Scottish Government Health Directorates
Keywords
NHS
SCOTLAND;DRUG THERAPY
TREATMENT
COST EFFECTIVENESS
MULTIPLE SCLEROSIS
PHARMACEUTICAL SERVICES
Description
This letter advises NHS Boards and Trusts that the UK Health Departments1 have reached agreement with manufacturers on a risksharing scheme for the supply of disease modifying treatments for Multiple Sclerosis (MS) on the NHS. The scheme involves detailed monitoring of a cohort of patients to confirm the cost-effectiveness of the treatments and the new arrangements will ensure that these supplies are cost-effective for NHSScotland. The Association of British Neurologists (ABN), the MS Society, the MS Trust, the UK MS Specialist Nurse Association and the Royal College of Nursing support the arrangements.
Linked to policy HDL(2002)06
Linked to policy HDL(2002)06
Contact Name
Contact Address
Pharmaceutical Issues<br> Mrs Mary Waugh,Tel: 0131-244 2870, email: mary.waugh@scotland.gsi.gov.uk<br> Policy on General MS Issues<br> Miss Kathleen Glancy, Tel: 0131-244 2544, email: kathleen.glancy@scotland.gsi.gov.uk
Created
2011-02-04 00:00:00
Click to go back to homepage